|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.08 USD | -0.65% |
|
-3.80% | -7.88% |
| Mar. 06 | Transcript : ESSA Pharma Inc. - Shareholder/Analyst Call | |
| Mar. 06 | Norway's wealth fund pushes for more women on emerging market company boards | RE |
ESSA Pharma Inc. reported earnings results for the full year ended September 30, 2022. For the full year, the company reported net loss was USD 35.1 million compared to USD 36.81 million a year ago. Basic loss per share from continuing operations was USD 0.8 compared to USD 0.96 a year ago.
Diluted loss per share from continuing operations was USD 0.8 compared to USD 0.96 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -7.88% | 269M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
ESSA PHARMA INC. 
